<DOC>
	<DOCNO>NCT00500357</DOCNO>
	<brief_summary>This follow-up study core study NCT00269672 ( 6115A1-500 ) . This study evaluate safety , tolerability , immunogenicity 13-valent pneumococcal conjugate vaccine ( 13vPnC ) administer subject already receive one dose 13vPnC , one dose 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) one year later . This study determine subsequent dose 13vPnC one year later result similar great immune response ( body 's ability protect disease ) measure initial dose 13vPnC .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Previous participant study 6115A1500 receive 13vPnC +AlPO4 / 23vPS Generally healthy male female adult 65 year age old Available duration trial approximately 1 month No history severe adverse reaction associate vaccine MMSE score less equal 21 exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>